SBIR/STTR Research Award

Controlling mechanical signal transduction to treat osteoarthritis

Award identifier 207f62558bbffdada44d3e67fae3def1cc7c4c5acfd70572154e97b4eae21f0bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$299,664

Program and phase

STTR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Cytex Therapeutics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
G9RMDCWJYGL3
Solicitation number
PA12-089
Topic code
NIA

Research abstract

DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint load as in obesity, are known predisposing factors for development of osteoarthritis, a disease with major impact -health, socioeconomic - in the US and many other countries. Previous work, including our own, unambiguously links TRPV4 to osteoarthritis. TRPV4 appears to be a necessary and critical regulator of chondrocytes' response to mechanical loading in both health and disease. Thus, we propose to use selective modulators of TRPV4 to attenuate development of osteoarthritis. In this respect, we have developed several small molecule compounds that serve as selective agonists and antagonists of the channel. Thereforewe have the ability in effect to turn on and off the activity of the channel, providing a means of tuning the chondrocytes' sensitivity to mechanical loading. In this collaborative small business-academia effort we will explore the effects of these novelcompounds in cellular and animal models of articular injury. The goal is explicitly to identify TRPV4 modulators that can effectively tune signal transduction in chondrocytes so that the compounds will attenuate injury to chondrocytes and cartilage. We will assess whether these compounds have beneficial effects in an animal model of post-traumatic joint injury by mechanism of a temporary tuning of osmo-mechanotransduction, which ultimately will result in chondroprotection. The development of small moleculeagonists and antagonists of TRPV4 has important implications in the treatment of cartilage diseases such as osteoarthritis. As academia- small business collaborators, we envision to develop these compounds jointly and move them forward towards clinical trials. Beyond single-trauma induced joint injury, we also see as a clear target the more chronic joint injury facilitated by obesity. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Degenerative and post-traumatic osteoarthritis are human diseases with high relevance for US public health, with increasing impact due to a non-linear increase in prevalence. In this application we describe an approach based on availability of a manageable set of TRPV4-modulating compounds, and propose to test these compounds in cellular and animal models of articular injury. Our proposed academia-small business collaboration will position us favorably to move forward with well-characterized and effective small molecules, so that chondrocytes' osmo-mechanotransductionafter articular injury can be tuned in order to provide chemical chondroprotection, a hitherto unrealized therapeutic principle.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

22 SBIR/STTR records share this UEI (2007–2023). Reported award amounts total $18,271,228. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.